Changes in the oculas surface after hypotensive surgery

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Hundreds of studies are dedicated to the negative effects of glaucoma therapy on the ocular surface. At the same time, the state of the eye surface after successful hypotensive surgery, which resulted in the cessation or significant reduction of medical therapy, has not been studied.

AIM: To identify ocular surface changes after glaucoma surgery.

MATERIALS AND METHODS: The study group consisted of 475 consecutively enrolled patients who were operated during 2016–2020 in Saint Petersburg Multidisciplinary City Hospital No. 2 for primary open-angle unstable glaucoma, and then observed for 6 to 24 months. Trabeculectomy (TE) was used as the first hypotensive procedure (418 patients), as re-operation — TE (25 patients) or Ahmed valve implantation (32 patients) were chosen. Using statistical methods, the dynamics of symptoms (OSDI) and signs [tear film break-up time (TBUT) and reflex tear production defined by Schirmer I test] depending on outcome (“complete” or “partial” success and “total failure”) were analyzed.

RESULTS: The cessation of the pharmacological load due to the “complete success” of the surgery was accompanied by pronounced (two-fold) and long (for at least two years) decrease of OSDI scores. The obliged, even partial, return to instillations by patients, who were included into the subgroup of “partial success”, within six months, transformed the achieved differences into insignificant ones. TBUT at “complete” and “partial success” significantly increased at all end-points of the study, significantly differing from the similar indicator in the subgroup “total failure”. The results of the Schirmer I test against the background of “complete success” of the operation showed a statistically significant increase, compared to the baseline , delayed for six months, throughout the whole further follow-up period. Patients entering the “partial success” subgroup in 24 months after surgery, also showed a significant increase in tear secretion. The failure of glaucoma surgery was accompanied by a brief and insignificant improvement in all scores.

CONCLUSIONS: The hypotensive surgery, which lead to “complete success”, was accompanied by a significant improvement of the ocular surface state. Restart of local therapy reduces achieved results. Failure of surgical treatment is associated with minimal fluctuations of the studied parameters.

About the authors

Аnastasiia V. Аntonova

City Multidisciplinary Hospital No. 2; Saint Petersburg State University

Author for correspondence.
Email: dr.antonova.av@gmail.com
ORCID iD: 0000-0002-2639-2765
SPIN-code: 2166-3936

ophthalmologist, assistant of the Department of ENT Diseases and Ophthalmology

Russian Federation, Saint Petersburg; Saint Petersburg

Vadim P. Nikolaenko

City Multidisciplinary Hospital No. 2; Saint Petersburg State University

Email: dr.Nikolaenko@mail.ru
ORCID iD: 0000-0002-6393-1289
SPIN-code: 4906-2542

MD, Doc. Sci. (Med.), head of the Ophthalmology Department; professor Otorhinolaryngology and Ophthalmology Department of the Medical Faculty

Russian Federation, Saint Petersburg; Saint Petersburg

Vladimir V. Brzheskiy

St. Petersburg State Pediatric Medical University

Email: vvbrzh@yandex.ru
ORCID iD: 0000-0001-7361-0270

Dr. Sci. (Med.), head of the Ophthalmology Department

Russian Federation, Saint Petersburg

Aleksandr Ja. Vuks

Bekhterev Psychoneurological Research Institute

Email: ayavuks@bekhterev.ru
ORCID iD: 0000-0002-6700-0609

head specialist

Russian Federation, Saint Petersburg

References

  1. Brzheskiy VV. Glaukoma i sindrom “sukhogo glaza”. Moscow: Borges, 2018. 228 p. (In Russ.)
  2. Antonova AV, Nikolaenko VP, Brzheskiy VV. Realization of a cascade treatment algorithm for glaucoma in St. Petersburg. Russian Journal of Clinical Ophthalmology. 2021;21(3):123–128. (In Russ.) doi: 10.32364/2311-7729-2021-21-3-123-128
  3. Lavin MJ, Wormald RPL, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108(11):1543–1548. doi: 10.1001/archopht.1990.01070130045027
  4. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446–1454. doi: 10.1001/archopht.1994.01090230060021
  5. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112(11):1437–1445. doi: 10.1001/archopht.1994.01090230051020
  6. Holló G, Schmidl D, Hommer A. Referral for firstglaucoma surgery in Europe, the ReF-GS study. Eur J Ophthalmol. 2019;29(4) 406–416. doi: 10.1177/1120672118791937
  7. Avo-portal.ru [Internet]. Klinicheskie rekomendatsii. Glaukoma pervichnaya otkrytougol’naya [cited 2023 Mar 7]. Available at: http://avo-portal.ru/doc/fkr/item/246-glaukoma-otkrytougolnay (In Russ.)
  8. Erichev VP, Petrov SYu, Antonov AA, Volzhanin AV. International standards of clinical trials in glaucoma surgery. National Journal glaucoma. 2016;15(2):102–112. (In Russ.)
  9. Shaarawy T, Grehn F, Sherwood M. Guidelines on design and reporting of glaucoma surgical trials. World Glaucoma Association. Amsterdam: Kugler Publications, 2009.
  10. Actis AG, Rolle T. Ocular surface alterations and topical antiglaucomatous therapy: A review. Open Ophthalmol J. 2014;8:67–72. doi: 10.2174/1874364101408010067
  11. Aguayo Bonniard A, Yeung JY, Chan CC, Birt CM. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12(11):279–1289. doi: 10.1080/17425255.2016.1209481
  12. Baudouin C. Ocular Surface and External Filtration Surgery: Mutual Relationships. Dev Ophthalmol. 2017;59:67–79. doi: 10.1159/000458487
  13. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. doi: 10.1016/j.jtos.2017.05.011
  14. Sheppard JD, Nichols KK. Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape. Ophthalmol Ther. 2023; In Press. doi: 10.1007/s40123-023-00669-1
  15. Bartlett JD, Keith MS, Sudharshan L, Snedecor S. Associations between signs and symptoms of dry eye disease: a systematic review. Clin Ophthalmol. 2015;9:1719–1730. doi: 10.2147/OPTH.S89700
  16. Baudouin C, Rolando M, Benitez Del Castillo JM, et al. Reconsidering the central role of mucins in dry eye and ocular surface diseases. Prog Retin Eye Res. 2019;71:68–87. doi: 10.1016/j.preteyeres.2018.11.007
  17. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71–81. doi: 10.3238/arztebl.2015.0071
  18. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–283. doi: 10.1016/j.jtos.2017.05.008
  19. Tsubota K, Pflugfelder SC, Liu Z, et al. Defining Dry Eye from a Clinical Perspective. Int J Mol Sci. 2020;21(23):9271. doi: 10.3390/ijms21239271
  20. Mittal R, Patel S, Galor A. Alternative therapies for dry eye disease. Curr Opin Ophthalmol. 2021;32(4):348–361. doi: 10.1097/ICU.0000000000000768
  21. Periman LM, Perez VL, Saban DR, et al. The Immunological basis of Dry Eye Disease and current topical treatment options. J Ocul Pharmacol Ther. 2020;36(3):137–146. doi: 10.1089/jop.2019.0060
  22. Rao SK, Mohan R, Gokhale N, et al. Inflammation and dry eye disease-where are we? Int J Ophthalmol. 2022;15(5):820–827. doi: 10.18240/ijo.2022.05.20
  23. Аntonova АV, Nikolaenko VP, Brzheskiy VV, Vuks AJ. Factors influencing the effectiveness of trabeculectomy: following materials of the City Multidisciplinary Hospital No. 2. Ophthalmology Reports. 2022;15(4):35–44. (In Russ.) doi: 10.17816/OV159363

Copyright (c) 2023 Аntonova А.V., Nikolaenko V.P., Brzheskiy V.V., Vuks A.J.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies